Technical Analysis for CHRS - Coherus BioSciences, Inc.
|Grade||Last Price||% Change||Price Change|
CHRS closed down 2.99 percent on Friday, October 19, 2018, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 5
|See historical CHRS trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 19||Wide Bands||Range Expansion||0.00%|
|Oct 19||Down 3 Days in a Row||Weakness||0.00%|
|Oct 19||Oversold Stochastic||Weakness||0.00%|
|Oct 18||Hammer Candlestick||Bullish||-2.99%|
|Oct 18||Wide Bands||Range Expansion||-2.99%|
|Oct 18||Oversold Stochastic||Weakness||-2.99%|
|Oct 17||Wide Bands||Range Expansion||-5.08%|
|Oct 17||Oversold Stochastic||Weakness||-5.08%|
|Oct 16||Outside Day||Range Expansion||-7.85%|
|Oct 16||Wide Bands||Range Expansion||-7.85%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CHRS news...
|52 Week High||20.66|
|52 Week Low||8.05|
|200-Day Moving Average||14.392|
|50-Day Moving Average||17.0116|
|20-Day Moving Average||14.629|
|10-Day Moving Average||13.205|
|Average True Range||0.8304|
|Chandelier Exit (Long, 3 ATRs )||14.7588|
|Chandelier Exit (Short, 3 ATRs )||14.5312|
|Upper Bollinger Band||17.6345|
|Lower Bollinger Band||11.6235|
|Percent B (%b)||0.12|
|MACD Signal Line||-1.1321|
|Market Cap||633.1 Million|
|Num Shares||51.3 Million|
|Price-to-Earnings (P/E) Ratio||-4.74|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||13.67|
|Resistance 3 (R3)||13.72||13.32||13.44|
|Resistance 2 (R2)||13.32||12.98||13.30||13.37|
|Resistance 1 (R1)||12.83||12.77||12.63||12.78||13.29|
|Support 1 (S1)||11.94||12.09||11.74||11.89||11.37|
|Support 2 (S2)||11.54||11.88||11.52||11.29|
|Support 3 (S3)||11.05||11.54||11.22|
|Support 4 (S4)||11.00|